Greeks.live: Options Data Shows Market Sentiment is Optimistic, but Short-term Caution Remains
Greeks.live analyst Adam posted on social media, "May 16 options expiration data: 27,000 BTC options expired, Put Call Ratio is 1.03, max pain point is $100,000, nominal value is $2.76 billion. 220,000 ETH options expired, Put Call Ratio is 1.36, max pain point is $2,300, nominal value is $570 million.
This week's Bitcoin expiration data is almost identical to last week's, and Ethereum is similar except for price factors. The current market sentiment is very good, but options data shows that there are still not many mainstream coin holders, and the number of profit-takers is limited. Currently, Bitcoin's short to medium-term RV has fallen below 35%, with medium to long-term around 50%, but the drop in IV is more pronounced, almost all falling below 45%, so the VRP across all terms has actually retreated somewhat.
The expiration volume is less than 9% of the total open interest, and the proportion of put options this month remains high. This phenomenon may not see a significant change until June. The market is relatively optimistic about the upcoming trend, but there are not many people going long on BTC in the short term.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Coreweave discusses data center cooperation with South Korea
According to ZDNet, Coreweave (CRWV.US) is in discussions with South Korea regarding cooperation on data centers.
Sberbank of Russia reported a net profit of 168.5 billions rubles in September
Sberbank of Russia announced that, according to Russian accounting standards, its net profit for September was 168.5 billion rubles.
The yield on France's 10-year government bond dropped by 8 basis points to 4.82%.
France leads the eurozone bond market, with the 10-year government bond yield falling by 8 basis points to 4.82%.
Even with Eli Lilly's endorsement, TRex Bio (TRXB.US) struggles to enjoy a premium; IPO price falls to lower range at $14.
According to Zhitong Finance APP, TRex Bio Inc., an early-stage biotechnology company focused on autoimmune and inflammatory diseases, raised 116.7 million dollars through its IPO, pricing at the lower end of its indicated range.